# Super Vision

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/super-vision

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.supervisiontech.cn/
- Total disclosed funding: $22M
- Latest round: Series C (Mar 16, 2026)
- Investors on record: 11

## About

Based in Beijing, China and founded in 2018, Super Vision Technology, Inc., trading as Super Vision, is an ophthalmology medical device research and development company. It founded by Mr. Lejin Wang, a professor at Peking University people's hospital, and a leader in ophthalmology in China. In 2021, a clean workshop that invested nearly RMB 20 million was built for its production of implantable ocular muscle nerve stimulator medical devices. In March 2026, Super Vision raised a series C funding from Beyond Ventures.

Super Vision developed four product lines, which are used to cure myopia, glaucoma and pediatric ophthalmology. Its main products are implantable glaucoma micro drainage pump and eye muscle nerve stimulation debugging system. The therapeutic principle of the eye muscle nerve stimulation debugging system is derived from the functional electrical stimulation FES technology.

The company generates revenue by developing eye muscle nerve stimulators for congenital nystagmus.

The company will use the latest funding to advance the research and clinical trials of its implantable nystagmus electrical stimulator.

## Funding rounds

- Series C, Mar 16, 2026 — Beyond Ventures
- Series B, Feb 25, 2025 — Founder H Fund, Lapam Capital, Changkejin  Investment, Tsinghua Innovation Ventures, Fosun Health Capital, Tsingstone Capital
- Series A, Dec 7, 2022, $14M — Fosun Health Capital, Mingheng Industrial Investment
- Series A, Aug 6, 2021, $8.1M — Founder H Fund, Beijing Dongsheng Bozhan Investment Management, Ruisheng Equity Investment Fund Partnership, Tsinghua Innovation Ventures, Beijing Richest Investment Management

## Investors

- Founder H Fund (https://capitalatlas.ai/funds/founder-h-fund) — Series A, Series B
- Beijing Dongsheng Bozhan Investment Management (https://capitalatlas.ai/funds/beijing-dongsheng-bozhan-investment-management) — Series A
- Ruisheng Equity Investment Fund Partnership (https://capitalatlas.ai/funds/ruisheng-equity-investment-fund-partnership) — Series A
- Tsinghua Innovation Ventures (https://capitalatlas.ai/funds/tsinghua-innovation-ventures) — Series A, Series B
- Beijing Richest Investment Management (https://capitalatlas.ai/funds/beijing-richest-investment-management) — Series A
- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Series A, Series B
- Mingheng Industrial Investment — Series A
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series B
- Changkejin  Investment — Series B
- Tsingstone Capital (https://capitalatlas.ai/funds/tsingstone-capital) — Series B
- Beyond Ventures — Series C